38 related articles for article (PubMed ID: 25338967)
1. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
[TBL] [Abstract][Full Text] [Related]
2. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
3. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.
Thomas A; Gingrich RD; Smith BJ; Jacobus L; Ristow K; Allmer C; Maurer MJ; Habermann TM; Link BK
Leuk Lymphoma; 2010 Mar; 51(3):439-46. PubMed ID: 20141442
[TBL] [Abstract][Full Text] [Related]
4. Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using
Rankin S; Fountain C; Gemmell AJ; Quinn D; Henderson A; McClure J; Small S; Venugopal B; McKay P; Slomka PJ; Colville D; Petrie MC; Meléndez GC; Lang NN
bioRxiv; 2024 Jun; ():. PubMed ID: 38895275
[TBL] [Abstract][Full Text] [Related]
5. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
[TBL] [Abstract][Full Text] [Related]
7. How to Sequence Therapies in Peripheral T Cell Lymphoma.
Wudhikarn K; Bennani NN
Curr Treat Options Oncol; 2021 Jul; 22(9):74. PubMed ID: 34213653
[TBL] [Abstract][Full Text] [Related]
8. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N; Kirkwood AA; Lamb M; Smith A; Khwaja J; Manos K; Shrubsole C; Gray N; Lewis K; Tivey A; Bishton MJ; Hawkes E; Ahearne MJ; Osborne W; Collins GP; Illidge T; Linton KM; Cwynarski K; Burton C; Fox CP
Adv Ther; 2021 Jul; 38(7):3789-3802. PubMed ID: 34037958
[TBL] [Abstract][Full Text] [Related]
9. Controversies in the Treatment of Peripheral T-cell Lymphoma.
Bachy E; Broccoli A; Dearden C; de Leval L; Gaulard P; Koch R; Morschhauser F; Trümper L; Zinzani PL
Hemasphere; 2020 Oct; 4(5):e461. PubMed ID: 33062943
[TBL] [Abstract][Full Text] [Related]
10. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas.
Ahn SY; Jung SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Kang SR; Han YH; Kwak JY; Yhim HY; Yang DH
Ann Hematol; 2020 Jan; 99(1):83-91. PubMed ID: 31807859
[TBL] [Abstract][Full Text] [Related]
12. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
[TBL] [Abstract][Full Text] [Related]
13. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma.
Eslick R; Dunlop L; Lin M; Hsu D; Ling S
Blood Cancer J; 2017 Apr; 7(4):e556. PubMed ID: 28430171
[No Abstract] [Full Text] [Related]
15. Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
Tomita N; Hattori Y; Fujisawa S; Hashimoto C; Taguchi J; Takasaki H; Sakai R; Tateishi U; Ishigatsubo Y
Ann Hematol; 2015 Mar; 94(3):431-6. PubMed ID: 25338967
[TBL] [Abstract][Full Text] [Related]
16. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
18. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
19. Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long.
Moskowitz AJ; Lunning MA; Horwitz SM
Cancer J; 2012; 18(5):445-9. PubMed ID: 23006950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]